What is Mannkind's market cap?

Mannkind (MNKD) has a market capitalization of $1.2B and trades on NASDAQ.

What is Mannkind's revenue and profitability?

Mannkind generated $360.8M in trailing twelve-month revenue with net income of $5.2M, representing a net margin of 9.3%. Gross margin stands at 91.5%, with free cash flow of $16.4M. These figures are based on the Q1 2026 filing.

Who are Mannkind's competitors?

Mannkind's key competitors include Eli Lilly and Company, Lexicon Pharmaceuticals, Inc., MetaVia Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Mannkind partner with?

Mannkind's notable partners include United Therapeutics Corporation, Cipla Ltd., Amphastar France Pharmaceuticals S.A.S., and others.

What subsidiaries does Mannkind have?

Mannkind's subsidiaries include scPharmaceuticals Inc..

Where is Mannkind headquartered?

Mannkind is headquartered in United States of America and employs approximately 414 people. It has been publicly traded since 2004.

Mannkind

MNKD

MannKind Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative inhaled therapeutic solutions for cardiometabolic and orphan lung diseases.

Market cap

$1.19B-4.8%

Revenue$360.8M+21.2%

Net income$5.2M-81.2%

Free cash flow$16.4M-50.0%

EPS (diluted)$0.02-80.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$90.2MMiss by $15.2M EPS-$0.05Miss by $0.03

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$109.2M

EPS estimate-$0.02

Financials

Q1 2026

Income statement

See full

Revenue$90.2M+15.1%

Gross profit$82.7M+10.8%

Operating income-$1.7M-107%

Net income-$16.6M-226%

EPS (diluted)-$0.05-225%

Balance sheet

See full

Cash & equivalents$52.8M+11.7%

Total debt$12.2M-9.4%

Total equity-$59.2M-1.0%

Total assets$744.4M+81.5%

Cash flow

See full

Operating cash flow-$5.4M+15.9%

CapEx$1.9M+470%

Free cash flow-$7.2M-8.0%

Valuation & ratios

Valuation

See full

Market cap$1.19B-4.8%

Enterprise value$1.15B-4.7%

P/E228.5×—

P/S3.3×-0.8×

Profitability

See full

Gross margin91.5%-2.6pp

Returns & leverage

See full

Current ratio1.9×-0.5×

Segments

By product

See full

License And Service$23.5M-20.0%

Manufacturing Services$2.4M+700%

By segment

See full

All Other Segments$90.2M+15.1%

Competitors

By market cap

Eli Lilly$1.04T+44.6%

Abbott$175.17B-20.0%

Medtronic$104.82B-11.1%

Mineralys Therapeutics, Inc.$2.4B+174%

Mannkind$1.2B-4.8%

Lexicon Pharmaceuticals$999.4M+127%

Biomea Fusion, Inc.$93.3M-11.6%

MTV

MetaVia$8.2M-42.1%

By revenue growth

Lexicon Pharmaceuticals+123%

Eli Lilly+47.4%

Mannkind+21.2%

Medtronic+8.4%

Abbott+8.1%

By net margin

Eli Lilly34.99%+12.3pp

Medtronic13.2%-0.7pp

Abbott11.65%-20.8pp

Mannkind9.32%-7.8pp

Lexicon Pharmaceuticals-37.46%+531pp

Profile

MannKind Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative inhaled therapeutic solutions for cardiometabolic and orphan lung diseases. The company leverages its proprietary Technosphere dry-powder delivery platform and breath-powered inhaler technology to provide patient-centric alternatives to traditional injections. Its core value proposition lies in transforming chronic disease care through drug-device combinations that improve ease of use and therapeutic delivery.

Competitive position

A leader in inhaled insulin and dry-powder drug delivery technology, maintaining a significant intellectual property portfolio across cardiometabolic and pulmonary indications.

GeographiesUnited States, India, China

Customer segmentsPatients, Healthcare Providers, Pharmaceutical Companies

Business modelProduct Sales, Royalty, Contract Manufacturing, Licensing and Collaboration

SuppliersActive pharmaceutical ingredient suppliers, Specialized chemical manufacturers, Contract manufacturing organizations, Plastic-molding service providers

CustomersSpecialty pharmacies, Wholesale distributors, Hospitals, Retail pharmacies, Collaboration partners

CountryUnited States of America

Listed2004

Employees414.0

CEOMichael E. Castagna

SectorHealthcare

IndustryBiotechnology

Websitemannkindcorp.com

FilingsSEC EDGAR

Ask your AI about Mannkind.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Mannkind's market cap?: Mannkind (MNKD) has a market capitalization of $1.2B and trades on NASDAQ.
What is Mannkind's revenue and profitability?: Mannkind generated $360.8M in trailing twelve-month revenue with net income of $5.2M, representing a net margin of 9.3%. Gross margin stands at 91.5%, with free cash flow of $16.4M. These figures are based on the Q1 2026 filing.
Who are Mannkind's competitors?: Mannkind's key competitors include Eli Lilly and Company, Lexicon Pharmaceuticals, Inc., MetaVia Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Mannkind partner with?: Mannkind's notable partners include United Therapeutics Corporation, Cipla Ltd., Amphastar France Pharmaceuticals S.A.S., and others.
What subsidiaries does Mannkind have?: Mannkind's subsidiaries include scPharmaceuticals Inc..
Where is Mannkind headquartered?: Mannkind is headquartered in United States of America and employs approximately 414 people. It has been publicly traded since 2004.